TD Cowen Reiterates Buy Rating on Protagonist Therapeutics (PTGX)

July 1, 2026 9:13 AM

TD Cowen analyst Tara Bancroft reiterated a Buy rating and $100.00 price target on Protagonist Therapeutics (NASDAQ: PTGX).The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found